Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
Daniele Lapa,
Daria M. Grousova,
Giulia Matusali,
Silvia Meschi,
Francesca Colavita,
Aurora Bettini,
Giulia Gramigna,
Massimo Francalancia,
Anna Rosa Garbuglia,
Enrico Girardi,
Vincenzo Puro,
Andrea Antinori,
Anna V. Kovyrshina,
Inna V. Dolzhikova,
Dmitry V. Shcheblyakov,
Amir I. Tukhvatulin,
Olga V. Zubkova,
Vladimir A. Gushchin,
Denis Y. Logunov,
Boris S. Naroditsky,
Francesco Vaia,
Alexander L. Gintsburg
Affiliations
Daniele Lapa
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Daria M. Grousova
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Giulia Matusali
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Silvia Meschi
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Francesca Colavita
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Aurora Bettini
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Giulia Gramigna
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Massimo Francalancia
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Anna Rosa Garbuglia
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Enrico Girardi
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Vincenzo Puro
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Andrea Antinori
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Anna V. Kovyrshina
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Inna V. Dolzhikova
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Dmitry V. Shcheblyakov
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Amir I. Tukhvatulin
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Olga V. Zubkova
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Vladimir A. Gushchin
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Denis Y. Logunov
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Boris S. Naroditsky
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
Francesco Vaia
INMI “National Institute of Infectious Diseases” Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Alexander L. Gintsburg
FSBI “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia
The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on the neutralizing activity of vaccinated sera against the Omicron variant are currently being carried out in many laboratories. In this study, we have shown the neutralizing activity of sera against the SARS-CoV-2 Omicron variant compared to the reference Wuhan D614G variant in individuals vaccinated with two doses of Sputnik V up to 6 months after vaccination and in individuals who experienced SARS-CoV-2 infection either before or after vaccination. As a control to our study we also measured neutralizing antibody titers in individuals vaccinated with two doses of BNT162b2. The decrease in NtAb titers to the Omicron variant was 8.1-fold for the group of Sputnik V-vaccinated individuals. When the samples were stratified for the time period after vaccination, a 7.6-fold or 8.8-fold decrease in NtAb titers was noticed after up to 3 and 3-to-6 months after vaccination. We observed a 6.7- and 5-fold decrease in Sputnik V-vaccinated individuals experiencing asymptomatic or symptomatic infection, respectively. These results highlight the observation that the decrease in NtAb to the SARS-CoV-2 Omicron variant compared to the Wuhan variant occurs for different COVID-19 vaccines in use, with some showing no neutralization at all, confirming the necessity of a third booster vaccination.
